AGC (5201) IR Day 2024 Day 1 summary
Event summary combining transcript, slides, and related documents.
IR Day 2024 Day 1 summary
8 Jul, 2026Group Strategy and Financial Targets
Targeting ROE of 8% by 2026 to cover capital cost, with a focus on improving and stabilizing ROE through portfolio transformation and profitability enhancement in each business.
Strategic investments prioritized in growth businesses, with a JPY 200 billion strategic investment budget and over JPY 1 trillion operating cash flow envisioned.
2026 targets include ROE of 8%+, EBITDA of JPY 440 billion+, operating profit of 230.0 billion yen or higher, and debt-to-equity ratio of 0.5 or less, with 2030 targets as the long-term goal.
Capital allocation shifts from core to strategic businesses, with increased dividends (approx. 3% DOE) and potential share buybacks if attractive investments are lacking.
Strategic businesses to contribute the majority of group operating profit by 2026.
Status Quo Analysis, Direction, and Key Strategies
ROE is below capital cost, with a target to reach 8% by 2026 to surpass the cost of capital.
Focus on accelerating corporate transformation, maximizing value, and deepening sustainability management.
Promotion of digital transformation (DX) and strengthening management foundations.
Emphasis on evolving the ambidextrous strategy.
Capital Cost and Capital Return Analysis
Current ROE averages 4.8% over six years, below the 8% capital cost.
2026 ROE target is set at 8% or above to achieve a P/B ratio greater than 1.
Industry PBR averages 1.1x (simple) and 1.5x (weighted), with improvement targeted.
Latest events from AGC
- Q1 FY2026 delivered strong sales and profit growth, with all segments contributing to gains.5201
Q1 20268 Jul 2026 - FY2026 targets higher profit and ROE, led by Life Science recovery and cost controls.5201
Q4 20258 Jul 2026 - Targets 8% ROE and 10% ROCE by 2026, focusing on growth, reforms, and sustainability.5201
IR Day 2024 Day 231 Jan 2026 - Operating and net profit improved despite lower sales, with stable outlook and dividends.5201
Q3 20255 Nov 2025 - Targets net zero carbon by 2050, driven by innovation, ESG, and talent development.5201
ESG Update26 Sep 2025 - FY2025 outlook cut as Chemicals, Life Science, and Electronics underperform; profit rebounds.5201
Q2 20251 Aug 2025 - Global leader in glass, chemicals, and life sciences, driving innovation and sustainable growth.5201
Corporate Presentation7 Jul 2025 - Ambidextrous strategy and sustainability drive growth, digitalization, and profitability targets.5201
Company Presentation7 Jul 2025 - Life Science impairments and Russian exit led to a sharp H1 2024 net loss despite sales growth.5201
Q2 202413 Jun 2025